Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

JAMA

Volumn 308, Issue 3, 2012, Pages 247-256

  Shirani, Afsaneh ^a   Zhao, Yinshan ^b   Karim, Mohammad Ehsanul ^a   Evans, Charity ^a   Kingwell, Elaine ^a   Van Der Kop, Mia L ^a   Oger, Joel ^a   Gustafson, Paul ^a   Petkau, John ^a   Tremlett, Helen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON;

ADULT; ARTICLE; CANADA; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISABILITY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG USE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOCIAL STATUS; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84863895902     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.7625     Document Type: Article

References (46)

1. PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-1504.
2. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 2003;361(9357):545- 552. (Pubitemid 36207471)
3. Haynes B. Can it work? does it work? is it worth it? the testing of healthcare interventions is evolving. BMJ. 1999;319(7211):652-653.
4. Arbizu T, Alvarez-Cermeño JC, Decap G, et al. Interferon beta-1b treatment in patients with relapsing-remitting multiple sclerosis under a standardized protocol in Spain. Acta Neurol Scand. 2000;102(4):209-217.
5. Brown MG, Kirby S, Skedgel C, et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology. 2007;69(15):1498-1507. (Pubitemid 47537856)
6. Coppola G, Lanzillo R, Florio C, et al. Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis. Eur J Neurol. 2006;13(9):1014-1021. (Pubitemid 44284911)
7. Milanese C, La Mantia L, Palumbo R, et al North Italy Multiple Sclerosis Group. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry. 2003;74(12):1689-1692. (Pubitemid 37542062)
8. Paolillo A, Pozzilli C, Giugni E, et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with interferon-beta. Eur J Neurol. 2002;9(6):645-655. (Pubitemid 36961292)
9. Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Neurol Sci. 2005;26(suppl 4):S174-S178. (Pubitemid 43085206)
10. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol. 2007;61(4):300-306. (Pubitemid 46676729)
11. Gout O. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol. 2008;63(1):126-127.
12. KochM, Mostert J, De Keyser J, Tremlett H, Filippini G. Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis. Ann Neurol. 2008;63(1):125-127.
13. Renoux C, Suissa S. Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis. Ann Neurol. 2008;64(1):109-110.
14. Brenner SR, Brown MG, Kirby S, et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology. 2008;71(8):615-616.
15. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16(3):241-249. (Pubitemid 46431687)
16. Dimick JB, Livingston EH. Comparing treatments using observational study designs: what can we do about selection bias? Arch Surg. 2010;145(10):927.
17. Sadovnick AD, Ebers GC, Wilson RW, Paty DW. Life expectancy in patients attending multiple sclerosis clinics. Neurology. 1992;42(5):991-994.
18. Sweeney VP, Sadovnick AD, Brandejs V. Prevalence of multiple sclerosis in British Columbia. Can J Neurol Sci. 1986;13(1):47-51. (Pubitemid 16189888)
19. Tremlett H, Devonshire V. Is late-onset multiple sclerosis associatedwith a worse outcome? Neurology. 2006;67(6):954-959. (Pubitemid 44454584)
20. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology. 2005;65(12):1919-1923. (Pubitemid 43970111)
21. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology. 2006;66(2):172-177. (Pubitemid 43970148)
22. Tremlett H, Yinshan Zhao, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler. 2008;14(3):314-324. (Pubitemid 351676426)
23. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y; UBC Neurologists. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology. 2009;73(20):1616-1623.
24. Tremlett H, Zhao Y, Joseph J, Devonshire V; UBCMS Clinic Neurologists. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry. 2008;79(12):1368-1374.
25. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452. (Pubitemid 14237132)
26. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983;39(2):499-503. (Pubitemid 14267522)
27. Multiple Sclerosis Society of Canada. Treatments-modifying the disease course. http://mssociety.ca/en/treatments/modify.htm. Accessed July 8, 2011.
28. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
29. Wilkins R, Berthelot JM, Ng E. Trends in mortality by neighbourhood income in urban Canada from 1971 to 1996. Health Rep. 2002;13(suppl):1-27.
30. Trojano M, Liguori M, Paolicelli D, et al; Southern Italy MS Group. Interferon beta in relapsingremitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler. 2003;9(5):451-457. (Pubitemid 37287722)
31. Boggild M, Palace J, Barton P, et al. Multiple sclerosis risk sharing scheme: 2 year results of clinical cohort study with historical comparator. BMJ. 2009;339:b4677.
32. Haut ER, Pronovost PJ. Surveillance bias in outcomes reporting. JAMA. 2011;305(23):2462-2463.
33. Stürmer T, Jonsson Funk M, Poole C, Brookhart MA. Nonexperimental comparative effectiveness research using linked healthcare databases. Epidemiology. 2011;22(3):298-301.
34. Rosenbaum PR. The role of a second control group in an observational study. Stat Sci. 1987;2(3):292-316.
35. Skoog B, Runmarker B, Winblad S, Ekholm S, AndersenO. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy. Brain. 2012;135(pt 3):900-911.
36. Shirani A, Zhao Y, Kingwell E, Rieckmann P, Tremlett H. Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009). Mult Scler. 2012;18(4):442-450.
37. Ebers GC, Traboulsee A, Li D, et al; Investigators of the 16-Year Long-Term Follow-up Study. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010;81(8):907-912.
38. Kappos L, FreedmanMS, Polman CH, et al BENEFIT Study Group. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8(11):987-997.
39. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006;67(6):944-953. (Pubitemid 44454583)
40. Uitdehaag B, Constantinescu C, Cornelisse P, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS longterm follow-up study. Ther Adv Neurol Disord. 2011;4(1):3-14.
41. Noseworthy JH. How much can we learn from long-term extension trials in multiple sclerosis? Neurology. 2006;67(6):930-931. (Pubitemid 44454578)
42. Berkman L, Epstein AM. Beyond health care - socioeconomic status and health. N Engl JMed. 2008;358(23):2509-2510. (Pubitemid 351793027)
43. Giovannoni G, Munschauer FE III, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002;73(5):465-469. (Pubitemid 35246792)
44. Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH.Disability as an outcome inMS clinical trials. Neurology. 2008;71(9):624-631.
45. Liu C, Blumhardt LD. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry. 2000;68(4):450-457. (Pubitemid 30248744)
46. Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: a critique. Neurology. 1988;38(11):1793-1798. (Pubitemid 18265050)